DK0909323T3
(da)
|
1996-01-04 |
2007-05-21 |
Novartis Vaccines & Diagnostic |
Helicobacter pylori-bakterioferritin
|
EP1328543B1
(fr)
|
2000-10-27 |
2009-08-12 |
Novartis Vaccines and Diagnostics S.r.l. |
Acides nucleiques et proteines derives des groupes de streptocoques a et b
|
EP2336368A1
(fr)
|
2000-12-07 |
2011-06-22 |
Novartis Vaccines and Diagnostics, Inc. |
Rétrovirus endogène à régulation positive dans le cancer de la prostate
|
TWI228420B
(en)
*
|
2001-05-30 |
2005-03-01 |
Smithkline Beecham Pharma Gmbh |
Novel vaccine composition
|
GB0115176D0
(en)
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
US8481043B2
(en)
|
2001-06-22 |
2013-07-09 |
Cpex Pharmaceuticals, Inc. |
Nasal immunization
|
GB0118249D0
(en)
|
2001-07-26 |
2001-09-19 |
Chiron Spa |
Histidine vaccines
|
GB0121591D0
(en)
|
2001-09-06 |
2001-10-24 |
Chiron Spa |
Hybrid and tandem expression of neisserial proteins
|
AR045702A1
(es)
|
2001-10-03 |
2005-11-09 |
Chiron Corp |
Composiciones de adyuvantes.
|
CA2476626A1
(fr)
|
2002-02-20 |
2003-08-28 |
Chiron Corporation |
Microparticules comprenant des molecules adsorbees qui contiennent polypeptides
|
US8518694B2
(en)
|
2002-06-13 |
2013-08-27 |
Novartis Vaccines And Diagnostics, Inc. |
Nucleic acid vector comprising a promoter and a sequence encoding a polypeptide from the endogenous retrovirus PCAV
|
GB0220194D0
(en)
|
2002-08-30 |
2002-10-09 |
Chiron Spa |
Improved vesicles
|
CA2501812C
(fr)
|
2002-10-11 |
2012-07-10 |
Mariagrazia Pizza |
Vaccins polypeptidiques offrant une large protection contre des lignees de meningocoques hypervirulentes
|
ATE466875T1
(de)
|
2002-11-15 |
2010-05-15 |
Novartis Vaccines & Diagnostic |
Unerwartete oberflächenproteine in neisseria meningitidis
|
GB0227346D0
(en)
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
EP2263687B1
(fr)
|
2002-12-27 |
2015-03-25 |
Novartis Vaccines and Diagnostics, Inc. |
Compositions immunogènes contenant des phospholipides
|
ES2411080T3
(es)
|
2003-01-30 |
2013-07-04 |
Novartis Ag |
Vacunas inyectables contra múltiples serogrupos de meningococos
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
ES2529736T3
(es)
|
2003-04-10 |
2015-02-25 |
Novartis Vaccines And Diagnostics, Inc. |
Composición inmunogénica que comprende una proteína espicular del coronavirus del SARS
|
ES2596553T3
(es)
|
2003-06-02 |
2017-01-10 |
Glaxosmithkline Biologicals Sa |
Composiciones inmunogénicas a base de micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido
|
US20060035242A1
(en)
|
2004-08-13 |
2006-02-16 |
Michelitsch Melissa D |
Prion-specific peptide reagents
|
GB0323103D0
(en)
|
2003-10-02 |
2003-11-05 |
Chiron Srl |
De-acetylated saccharides
|
RU2378010C2
(ru)
|
2003-10-02 |
2010-01-10 |
Новартис Вэксинес Энд Дайэгностикс С.Р.Л. |
Жидкие вакцины для множественных серогрупп менингококков
|
DE202005022108U1
(de)
|
2004-03-09 |
2013-11-12 |
Novartis Vaccines And Diagnostics, Inc. |
Influenza-Virus-Impfstoffe
|
GB0409745D0
(en)
|
2004-04-30 |
2004-06-09 |
Chiron Srl |
Compositions including unconjugated carrier proteins
|
BRPI0510315A
(pt)
|
2004-04-30 |
2007-10-16 |
Chiron Srl |
integração de vacinação com conjugado meningocócico
|
GB0410866D0
(en)
|
2004-05-14 |
2004-06-16 |
Chiron Srl |
Haemophilius influenzae
|
WO2006078294A2
(fr)
|
2004-05-21 |
2006-07-27 |
Novartis Vaccines And Diagnostics Inc. |
Vecteurs d'alphavirus pour vaccins contre pathogenes respiratoires
|
CA2571421A1
(fr)
|
2004-06-24 |
2006-01-05 |
Nicholas Valiante |
Composes utilises pour l'immunopotentialisation
|
US20090317420A1
(en)
|
2004-07-29 |
2009-12-24 |
Chiron Corporation |
Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
|
GB0424092D0
(en)
|
2004-10-29 |
2004-12-01 |
Chiron Srl |
Immunogenic bacterial vesicles with outer membrane proteins
|
HUE033196T2
(en)
|
2005-01-27 |
2017-11-28 |
Children's Hospital & Res Center At Oakland |
GNA1870-based vesicle vaccines for broad-spectrum protection against diseases caused by Neisseria meningitidis
|
GB0502095D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Conjugation of streptococcal capsular saccharides
|
HUE027400T2
(en)
|
2005-02-18 |
2016-10-28 |
Glaxosmithkline Biologicals Sa |
Proteins and nucleic acids from meningitis / sepsis with Escherichia coli
|
ES2385045T3
(es)
|
2005-02-18 |
2012-07-17 |
Novartis Vaccines And Diagnostics, Inc. |
Inmunógenos de Escherichia coli uropatogénica
|
US20090130127A1
(en)
|
2005-08-01 |
2009-05-21 |
Seiji Tokumoto |
Adjuvant or Pharmaceutical Preparation for Transdermal or Transmucousal Administration
|
WO2007047749A1
(fr)
|
2005-10-18 |
2007-04-26 |
Novartis Vaccines And Diagnostics Inc. |
Immunisations mucosiques et systemiques avec particules de replicon d’alphavirus
|
US11707520B2
(en)
|
2005-11-03 |
2023-07-25 |
Seqirus UK Limited |
Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
|
US20100158943A1
(en)
*
|
2005-11-04 |
2010-06-24 |
Novartis Vaccines And Diagnostics Srl |
Administration routes for priming/boosting with influenza vaccines
|
CA2628152C
(fr)
|
2005-11-04 |
2016-02-02 |
Novartis Vaccines And Diagnostics S.R.L. |
Vaccins avec adjuvant comprenant des antigenes sans virions prepares a partir de virus influenza eleves en culture cellulaire
|
EP2360175B1
(fr)
|
2005-11-22 |
2014-07-16 |
Novartis Vaccines and Diagnostics, Inc. |
Particules de type virus (vlps) de norovirus et de sapovirus
|
GB0524066D0
(en)
|
2005-11-25 |
2006-01-04 |
Chiron Srl |
741 ii
|
PL1976559T6
(pl)
|
2006-01-27 |
2020-08-10 |
Novartis Influenza Vaccines Marburg Gmbh |
Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy
|
US8535683B2
(en)
|
2006-03-22 |
2013-09-17 |
Abbott Biologicals B.V. |
Intranasal or inhalational administration of virosomes
|
EP2357184B1
(fr)
|
2006-03-23 |
2015-02-25 |
Novartis AG |
Composés d'imidazoquinoxaline en tant qu'immunomodulateurs
|
JP2009534303A
(ja)
*
|
2006-03-24 |
2009-09-24 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー |
冷蔵しないインフルエンザワクチンの保存
|
US20100285062A1
(en)
|
2006-03-31 |
2010-11-11 |
Novartis Ag |
Combined mucosal and parenteral immunization against hiv
|
US20110206692A1
(en)
|
2006-06-09 |
2011-08-25 |
Novartis Ag |
Conformers of bacterial adhesins
|
GB0614460D0
(en)
|
2006-07-20 |
2006-08-30 |
Novartis Ag |
Vaccines
|
EP2586790A3
(fr)
|
2006-08-16 |
2013-08-14 |
Novartis AG |
Immunogènes d'Escherischia coli pathogènes des voies urinaires
|
CA2663196A1
(fr)
|
2006-09-11 |
2008-03-20 |
Novartis Ag |
Fabrication de vaccins contre le virus grippal sans utiliser d'oeufs
|
JP2011506264A
(ja)
|
2006-12-06 |
2011-03-03 |
ノバルティス アーゲー |
インフルエンザウイルスの4つの株に由来する抗原を含むワクチン
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
JP5275047B2
(ja)
*
|
2007-01-31 |
2013-08-28 |
久光製薬株式会社 |
経皮または経粘膜投与のためのアジュバントおよびこれを含む医薬製剤
|
SI2185191T1
(sl)
|
2007-06-27 |
2012-12-31 |
Novartis Ag |
Cepiva proti influenci z majhnimi dodatki
|
GB0713880D0
(en)
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
GB0810305D0
(en)
|
2008-06-05 |
2008-07-09 |
Novartis Ag |
Influenza vaccination
|
US8815253B2
(en)
|
2007-12-07 |
2014-08-26 |
Novartis Ag |
Compositions for inducing immune responses
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
CN104292312A
(zh)
|
2007-12-21 |
2015-01-21 |
诺华股份有限公司 |
链球菌溶血素o的突变形式
|
EP2245048B1
(fr)
|
2008-02-21 |
2014-12-31 |
Novartis AG |
Polypeptides fhbp à méningocoques
|
EP2265640B1
(fr)
|
2008-03-10 |
2015-11-04 |
Children's Hospital & Research Center at Oakland |
Protéines chimères de liaison du facteur h contenant un domaine b hétérologue, et procédés d utilisation associés
|
EP2376108B1
(fr)
|
2008-12-09 |
2017-02-22 |
Pfizer Vaccines LLC |
Vaccin peptidique de ige ch3
|
MX2011007456A
(es)
|
2009-01-12 |
2011-08-03 |
Novartis Ag |
Antigenos del dominio de proteina de superficie de union a colageno tipo b (can_b) en vacunas contra bacteria gram positiva.
|
AU2010212550B2
(en)
|
2009-02-10 |
2016-03-10 |
Seqirus UK Limited |
Influenza vaccines with reduced amounts of squalene
|
US8568732B2
(en)
|
2009-03-06 |
2013-10-29 |
Novartis Ag |
Chlamydia antigens
|
SG175092A1
(en)
|
2009-04-14 |
2011-11-28 |
Novartis Ag |
Compositions for immunising against staphylococcus aerus
|
BRPI1014494A2
(pt)
|
2009-04-30 |
2016-08-02 |
Coley Pharm Group Inc |
vacina pneumocócica e usos da mesma
|
DK2442826T3
(en)
|
2009-06-15 |
2015-09-21 |
Univ Singapore |
Influenza vaccine, composition and methods of using
|
SG177533A1
(en)
|
2009-07-07 |
2012-02-28 |
Novartis Ag |
Conserved escherichia coli immunogens
|
HRP20220756T1
(hr)
|
2009-07-15 |
2022-09-02 |
Glaxosmithkline Biologicals S.A. |
Proteinski pripravci rsv f i postupci za izradu istih
|
SG178035A1
(en)
|
2009-07-16 |
2012-03-29 |
Novartis Ag |
Detoxified escherichia coli immunogens
|
PE20120817A1
(es)
|
2009-07-30 |
2012-07-07 |
Pfizer Vaccines Llc |
Peptidos tau antigenicos y usos de los mismos
|
AU2010288240B2
(en)
|
2009-08-27 |
2014-03-27 |
Novartis Ag |
Hybrid polypeptides including meningococcal fHBP sequences
|
PE20161560A1
(es)
|
2009-09-03 |
2017-01-11 |
Pfizer Vaccines Llc |
Vacuna de pcsk9
|
JP2013506651A
(ja)
|
2009-09-30 |
2013-02-28 |
ノバルティス アーゲー |
Staphylococcus.aureus5型および8型莢膜多糖の結合体
|
GB0918392D0
(en)
|
2009-10-20 |
2009-12-02 |
Novartis Ag |
Diagnostic and therapeutic methods
|
AU2010310985B2
(en)
|
2009-10-27 |
2014-11-06 |
Glaxosmithkline Biologicals S.A. |
Modified meningococcal fHBP polypeptides
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
EP3257525A3
(fr)
|
2009-12-22 |
2018-02-28 |
Celldex Therapeutics, Inc. |
Compositions vaccinales
|
EP2519265B1
(fr)
|
2009-12-30 |
2018-11-14 |
GlaxoSmithKline Biologicals SA |
Immunogènes de polysaccharide conjugués à des protéines porteuses de e. coli
|
GB201003333D0
(en)
|
2010-02-26 |
2010-04-14 |
Novartis Ag |
Immunogenic proteins and compositions
|
CN102834410B
(zh)
|
2010-03-30 |
2016-10-05 |
奥克兰儿童医院及研究中心 |
改性的h因子结合蛋白(fhbp)及其使用方法
|
GB201005625D0
(en)
|
2010-04-01 |
2010-05-19 |
Novartis Ag |
Immunogenic proteins and compositions
|
WO2011130379A1
(fr)
|
2010-04-13 |
2011-10-20 |
Novartis Ag |
Compositions de benzonapthyridine et leurs utilisations
|
JP2013532008A
(ja)
|
2010-05-28 |
2013-08-15 |
テトリス オンライン インコーポレイテッド |
対話式ハイブリッド非同期コンピュータ・ゲーム・インフラストラクチャ
|
CA2800774A1
(fr)
|
2010-06-07 |
2011-12-15 |
Pfizer Vaccines Llc |
Vaccin peptidique ige ch3
|
CA2798837A1
(fr)
|
2010-06-07 |
2011-12-15 |
Pfizer Inc. |
Peptides her-2 et vaccins
|
GB201009861D0
(en)
|
2010-06-11 |
2010-07-21 |
Novartis Ag |
OMV vaccines
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
US20130171185A1
(en)
|
2010-07-06 |
2013-07-04 |
Ethan Settembre |
Norovirus derived immunogenic compositions and methods
|
GB201101665D0
(en)
|
2011-01-31 |
2011-03-16 |
Novartis Ag |
Immunogenic compositions
|
WO2012072769A1
(fr)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Epitopes rrgb de pneumocoque et combinaisons de variantes
|
CA2860331A1
(fr)
|
2010-12-24 |
2012-06-28 |
Novartis Ag |
Composes
|
TR201908715T4
(tr)
|
2011-01-26 |
2019-07-22 |
Glaxosmithkline Biologicals Sa |
Rsv immünizasyon rejimi.
|
US20140004142A1
(en)
|
2011-03-02 |
2014-01-02 |
Pfizer Inc. |
Pcsk9 vaccine
|
PL2707385T3
(pl)
|
2011-05-13 |
2018-03-30 |
Glaxosmithkline Biologicals Sa |
Prefuzyjne antygeny RSV F
|
US11896636B2
(en)
|
2011-07-06 |
2024-02-13 |
Glaxosmithkline Biologicals Sa |
Immunogenic combination compositions and uses thereof
|
EP2729168A2
(fr)
|
2011-07-06 |
2014-05-14 |
Novartis AG |
Compositions immunogènes et leurs utilisations
|
WO2013016460A1
(fr)
|
2011-07-25 |
2013-01-31 |
Novartis Ag |
Compositions et procédés d'évaluation de l'immunogénicité fonctionnelle de vaccins contre un parvovirus
|
EP2659908A1
(fr)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
EP2659906A1
(fr)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
EP2659907A1
(fr)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
MX359257B
(es)
|
2012-05-04 |
2018-09-19 |
Pfizer |
Antígenos asociados a próstata y regímenes de inmunoterapia basados en vacuna.
|
SG11201407440WA
(en)
|
2012-05-22 |
2014-12-30 |
Novartis Ag |
Meningococcus serogroup x conjugate
|
JP2015522580A
(ja)
|
2012-07-06 |
2015-08-06 |
ノバルティス アーゲー |
免疫学的組成物およびその使用
|
EA201590427A1
(ru)
|
2012-10-02 |
2015-09-30 |
Глаксосмитклайн Байолоджикалс С.А. |
Нелинейные сахаридные конъюгаты
|
SG11201500979RA
(en)
|
2012-10-03 |
2015-07-30 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
US9987344B2
(en)
|
2012-11-30 |
2018-06-05 |
Glaxosmithkline Biologicals Sa |
Pseudomonas antigens and antigen combinations
|
US20210145963A9
(en)
|
2013-05-15 |
2021-05-20 |
The Governors Of The University Of Alberta |
E1e2 hcv vaccines and methods of use
|
US9993549B2
(en)
|
2013-10-31 |
2018-06-12 |
Hisamitsu Pharmaceutical Co., Inc. |
Adjuvant composition, adjuvant preparation containing same, and kit
|
EP3096785B1
(fr)
|
2014-01-21 |
2020-09-09 |
Pfizer Inc |
Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2015123291A1
(fr)
|
2014-02-11 |
2015-08-20 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Vaccin à base de pcsk9 et méthodes d'utilisation dudit vaccin
|
EP4074726A3
(fr)
|
2014-07-23 |
2022-11-23 |
Children's Hospital & Research Center at Oakland |
Variants de protéines de liaison au facteur h et leurs procédés d'utilisation
|
DK3244917T5
(da)
|
2015-01-15 |
2024-10-14 |
Pfizer Inc |
Immunogene sammensætninger til anvendelse i pneumokokvacciner
|
AU2016271857B2
(en)
|
2015-06-03 |
2020-05-28 |
Affiris Ag |
IL-23-P19 vaccines
|
EP3319988A1
(fr)
|
2015-07-07 |
2018-05-16 |
Affiris AG |
Vaccins pour le traitement et la prévention de maladies médiées par ige
|
PE20180657A1
(es)
|
2015-07-21 |
2018-04-17 |
Pfizer |
Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos
|
CA3005524C
(fr)
|
2015-11-20 |
2023-10-10 |
Pfizer Inc. |
Compositions immunogenes destinees a etre utilisees dans des vaccins pneumococciques
|
JP6820935B2
(ja)
|
2016-01-19 |
2021-01-27 |
ファイザー・インク |
がんワクチン
|
SI3570879T1
(sl)
|
2017-01-20 |
2022-06-30 |
Pfizer Inc. |
Imunogenska kompozicija za uporabo v pnevmokoknih cepivih
|
WO2019173438A1
(fr)
|
2018-03-06 |
2019-09-12 |
Stc. Unm |
Compositions et méthodes pour faire baisser les triglycérides sériques
|
US11260119B2
(en)
|
2018-08-24 |
2022-03-01 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
JP2022512345A
(ja)
|
2018-12-12 |
2022-02-03 |
ファイザー・インク |
免疫原性多重ヘテロ抗原多糖-タンパク質コンジュゲートおよびその使用
|
JP7239509B6
(ja)
|
2019-02-22 |
2023-03-28 |
ファイザー・インク |
細菌多糖類を精製するための方法
|
US20220184199A1
(en)
|
2019-04-10 |
2022-06-16 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
IL292494A
(en)
|
2019-11-01 |
2022-06-01 |
Pfizer |
Preparations of Escherichia coli and their methods
|
WO2021165847A1
(fr)
|
2020-02-21 |
2021-08-26 |
Pfizer Inc. |
Purification de saccharides
|
EP4107170A2
(fr)
|
2020-02-23 |
2022-12-28 |
Pfizer Inc. |
Escherichia coli compositions d'et méthodes associées
|
EP4114848A4
(fr)
|
2020-02-26 |
2024-04-03 |
Versitech Limited |
Vaccins à base de pd-1 dirigés contre une infection à coronavirus
|
IL302362A
(en)
|
2020-10-27 |
2023-06-01 |
Pfizer |
ESCHERICHIA COLI preparations and their methods
|
CN116744965A
(zh)
|
2020-11-04 |
2023-09-12 |
辉瑞大药厂 |
用于肺炎球菌疫苗的免疫原性组合物
|
EP4243863A2
(fr)
|
2020-11-10 |
2023-09-20 |
Pfizer Inc. |
Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations
|
TWI750929B
(zh)
*
|
2020-12-02 |
2021-12-21 |
林建宏 |
氣霧免疫用之溫敏型佐劑及其製作方法
|
US20220202923A1
(en)
|
2020-12-23 |
2022-06-30 |
Pfizer Inc. |
E. coli fimh mutants and uses thereof
|
WO2022147373A1
(fr)
|
2020-12-31 |
2022-07-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Immunogènes imitant la pcsk9 guidés par des anticorps et ne présentant pas de chevauchement de séquence de 9 résidus avec des protéines humaines
|
TW202245836A
(zh)
|
2021-02-19 |
2022-12-01 |
美商賽諾菲巴斯德公司 |
重組b型腦膜炎球菌疫苗
|
EP4333868A1
(fr)
|
2021-05-04 |
2024-03-13 |
King Abdullah University Of Science And Technology |
Compositions immuogéniques de protéine n mutante de sars-cov-2 et gène et procédés d'utilisation associés
|
JP2024522395A
(ja)
|
2021-05-28 |
2024-06-19 |
ファイザー・インク |
コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
|
US20220387576A1
(en)
|
2021-05-28 |
2022-12-08 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2023079529A1
(fr)
|
2021-11-05 |
2023-05-11 |
King Abdullah University Of Science And Technology |
Compositions d'immunisation de rappel de protéine de refocalisation et leurs méthodes d'utilisation
|
WO2023079528A1
(fr)
|
2021-11-05 |
2023-05-11 |
King Abdullah University Of Science And Technology |
Compositions appropriées pour une utilisation dans un procédé pour déclencher une immunité protectrice croisée contre des coronavirus
|
IL312890A
(en)
|
2021-11-18 |
2024-07-01 |
Matrivax Inc |
Immunogenic fusion protein preparations and methods of using them
|
AU2023207315A1
(en)
|
2022-01-13 |
2024-06-27 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2023161817A1
(fr)
|
2022-02-25 |
2023-08-31 |
Pfizer Inc. |
Procédés d'incorporation de groupes azido dans des polysaccharides capsulaires bactériens
|
WO2023218322A1
(fr)
|
2022-05-11 |
2023-11-16 |
Pfizer Inc. |
Procédé de production de formulations de vaccin avec des conservateurs
|
WO2024018061A1
(fr)
|
2022-07-22 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Utilisation de souches de bordetella pour le traitement de la bronchopneumopathie chronique obstructive
|
WO2024110827A1
(fr)
|
2022-11-21 |
2024-05-30 |
Pfizer Inc. |
Procédés de préparation d'antigènes saccharidiques capsulaires conjugués et leurs utilisations
|
US20240181028A1
(en)
|
2022-11-22 |
2024-06-06 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2024116096A1
(fr)
|
2022-12-01 |
2024-06-06 |
Pfizer Inc. |
Formulations de vaccin pneumococcique conjugué
|
WO2024130009A1
(fr)
|
2022-12-14 |
2024-06-20 |
Yale University |
Compositions et leurs procédés d'utilisation pour le traitement de cancers entraînés par un virus
|
WO2024166008A1
(fr)
|
2023-02-10 |
2024-08-15 |
Pfizer Inc. |
Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations
|
WO2024201324A2
(fr)
|
2023-03-30 |
2024-10-03 |
Pfizer Inc. |
Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et utilisations associées
|